Search

Your search keyword '"Lebray, Pascal"' showing total 332 results
Start Over Author "Lebray, Pascal"
332 results on '"Lebray, Pascal"'

51. Efficacy of Sofosbuvir and Daclatasvir in Patients With Fibrosing Cholestatic Hepatitis C After Liver Transplantation

Author

Leroy, Vincent, Dumortier, Jérôme, Coilly, Audrey, Sebagh, Mylène, Fougerou-Leurent, Claire, Radenne, Sylvie, Botta, Danielle, Durand, François, Silvain, Christine, Lebray, Pascal, Houssel-Debry, Pauline, Kamar, Nassim, DʼAlteroche, Louis, Petrov-Sanchez, Ventzislava, Diallo, Alpha, Pageaux, Georges-Philippe, Duclos-Vallee, Jean-Charles, Bellissant, Eric, Botta-Fridlund, Danielle, Dumortier, Jérôme, Duvoux, Christophe, Fougerou-Leurent, Claire, Renault, Alain, Rohel, Alexandra, Roque, Anne-Marie, Taburet, Anne-Marie, and Veislinger, Aurélie

Published
2015
Full Text
View/download PDF

52. Significant Variations in Elastometry Measurements Made Within Short-term in Patients With Chronic Liver Diseases

Author

Nascimbeni, Fabio, Lebray, Pascal, Fedchuk, Larysa, Oliveira, Claudia P., Alvares-da-Silva, Mario Reis, Varault, Anne, Ingiliz, Patrick, Ngo, Yen, de Torres, Mercedes, Munteanu, Mona, Poynard, Thierry, Ratziu, Vlad, Grimaldi, André, Giral, Philippe, Bruckert, Eric, Basdevant, Arnaud, Clement, Karine, Oppert, Jean-Michel, Hartemann-Heurtier, Agnès, Andreelli, Fabrizio, Gombert, Sophie, Jacqueminet, Sophie, Cocaul, Arnaud, Fouffelle, Fabienne, Moussalli, Joseph, Thabut, Dominique, Podevin, Philippe, Bonnefont-Rousselot, Dominique, Bittar, Randa, Benhamou, Yves, Bernhardt, Carole, Boitard, Christian, Larger, Etienne, Sola, Agnès, El-Etr, Martine, Gautier, Jean-François, Serfaty, Lawrence, Housset, Chantal, and Capeau, Jacqueline

Published
2015
Full Text
View/download PDF

62. Hepatitis B virus reactivation in transplant patients treated for hepatitis C recurrence: Prophylaxis makes the difference

Author

Mouna, Lina, Rossignol, Emilie, Tateo, Mariagrazia, Coilly, Audrey, Duclos-Vallée, Jean-Charles, Duvoux, Christophe, Durand, François, Tran, Albert, Radenne, Sylvie, Canva-Delcambre, Valerie, Houssel-Debry, Pauline, Dumortier, Jérôme, Conti, Filomena, de Ledinghen, Victor, Leroy, Vincent, Kamar, Nassim, Di Martino, Vincent, Moreno, Christophe, Botta Fridlund, Danielle, d'Alteroche, Louis, Lebray, Pascal, Perre, Philippe, Besch, Camille, Silvain, Christine, Habersetzer, François, Debette-Gratien, Maryline, Abergel, Armando, Diallo, Alpha, Samuel, Didier, Roque-Afonso, Anne-Marie, and Pageaux, Georges-Philippe

Published
2019
Full Text
View/download PDF

70. 12 weeks of a Ribavirin-free Sofosbuvir and NS5A inhibitor regimen is enough to treat recurrence of hepatitis C after liver transplantation

Author

Houssel-Debry, Pauline, Coilly, Audrey, Fougerou-Leurent, Claire, Jezequel, Caroline, Duvoux, Christophe, De Ledinghen, Victor, Radenne, Sylvie, Kamar, Nassim, Leroy, Vincent, Di Martino, Vincent, D'Alteroche, Louis, Canva, Valérie, Conti, Filomena, Dumortier, Jerome, Montialoux, Hélène, Lebray, Pascal, Botta-Fridlund, Danielle, Tran, Albert, Moreno, Christophe, Silvain, Christine, Besch, Camille, perre, philippe, Francoz, Claire, Abergel, Armando, Habersetzer, François, Debette-Gratien, Maryline, Cagnot, Carole, Diallo, Alpha, Chevaliez, Stéphane, Rossignol, Emilie, Veislinger, Aurelie, Duclos-Vallee, Jean-Charles, Pageaux, Georges-Philippe, CHU Pontchaillou [Rennes], Physiopathologie et traitement des maladies du foie, Université Paris-Sud - Paris 11 (UP11)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Paul Brousse, Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Henri Mondor, Physiopathologie du cancer du foie, Université Bordeaux Segalen - Bordeaux 2-Institut National de la Santé et de la Recherche Médicale (INSERM), Service d'Hépatologie [Hôpital de la Croix-Rousse - HCL], Hôpital de la Croix-Rousse [CHU - HCL], Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), Centre de Physiopathologie Toulouse Purpan (CPTP), Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), CHU Grenoble, Service d'hépatologie, Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), CHU Rouen, Normandie Université (NU), Université libre de Bruxelles (ULB), Centre hospitalier universitaire de Poitiers (CHU Poitiers), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7)-Hôpital Beaujon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), CHU Clermont-Ferrand, Interactions Virus-Hôte et Maladies Hépatiques, Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut de Virologie, Service d'Hépato-Gastro-Entérologie et Nutrition [CHU Limoges], CHU Limoges, ANRS France Recherche Nord & sud Sida-hiv hépatites, Université Paris-Sud - Paris 11 ( UP11 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -AP-HP Hôpital Paul Brousse, Centre d'Investigation Clinique [Rennes] ( CIC ), Université de Rennes 1 ( UR1 ), Université de Rennes ( UNIV-RENNES ) -Université de Rennes ( UNIV-RENNES ) -Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Université Bordeaux Segalen - Bordeaux 2-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Hospices Civils de Lyon ( HCL ) -Hospices Civils de Lyon ( HCL ), Centre de physiopathologie de Toulouse Purpan ( CPTP ), Université Paul Sabatier - Toulouse 3 ( UPS ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Centre National de la Recherche Scientifique ( CNRS ), Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Hôpital Jean Minjoz-Université de Franche-Comté ( UFC ), Centre Hospitalier Régional Universitaire de Tours ( CHRU TOURS ), Université Libre de Bruxelles [Bruxelles] ( ULB ), CHU de Poitiers, Assistance publique - Hôpitaux de Paris (AP-HP)-Université Paris Diderot - Paris 7 ( UPD7 ) -Hôpital Beaujon, Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Institut de Virologie, ANRS, ANRS (France Recherche Nord & Sud Sida-HIV Hépatites), Paris, France, Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Henri Mondor [Créteil], Université de Toulouse (UT)-Université de Toulouse (UT)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre National de la Recherche Scientifique (CNRS), Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), and Centre Hospitalier Régional Universitaire de Tours (CHRU TOURS)

Subjects
treatment duration, [ SDV ] Life Sciences [q-bio], viruses, ANRS CO23 CUPILT cohort, [SDV]Life Sciences [q-bio], Ribavirin use, virus diseases, Direct-acting antiviral agents, biochemical phenomena, metabolism, and nutrition, digestive system diseases
Abstract

International audience; Sofosbuvir (SOF) combined with NS5A inhibitors has demonstrated its efficacy in treating a recurrence of HCV after liver transplantation. However, the duration of treatment and the need for ribavirin (RBV) remain unclear in this population. Our aim was to determine whether liver transplant recipients could be treated with an SOF+NS5A inhibitor-based regimen without RBV for 12 weeks after liver transplantation (LT).

Published
2018
Full Text
View/download PDF

71. SAT-248-Patients treated for HCV and listed for LT in a French multicenter study: What happens at 3 years?

Author

Meunier, Lucy, primary, Pageaux, Georges-Philippe, additional, Radenne, Sylvie, additional, Pichard, Anais Vallet, additional, Houssel-Debry, Pauline, additional, Duvoux, Christophe, additional, Fridlund, Danielle Botta, additional, Ledinghen, Victor De, additional, Conti, Filomena, additional, Anty, Rodolphe, additional, Martino, Vincent Di, additional, Gratien, Marilyne, additional, Leroy, Vincent, additional, Lebray, Pascal, additional, Alric, Laurent, additional, Abergel, Armand, additional, Dumortier, Jérôme, additional, Besch, Camille, additional, Helene, Montialoux, additional, Samuel, Didier, additional, Duclos-Vallée, Jean-Charles, additional, and Coilly, Audrey, additional

Published
2019
Full Text
View/download PDF

73. Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest)

Author

Bismut Françoise, Messous Djamila, Drane Fabienne, Munteanu Mona, Norha Pascal, Ngo Yen, Varsat Brigitte, Varaut Anne, Ingiliz Patrick, Lebray Pascal, Poynard Thierry, Carrau Jean, Massard Julien, Ratziu Vlad, and Giordanella Jean

Subjects
Diseases of the digestive system. Gastroenterology, RC799-869
Abstract

Abstract Background FibroTest and elastography have been validated as biomarkers of liver fibrosis in the most frequent chronic liver diseases and in the fibrosis screening of patients with diabetes. One challenge was to use them for estimating the prevalence of fibrosis, identifying independent risk factors and to propose screening strategies in the general population. Methods We prospectively studied 7,463 consecutive subjects aged 40 years or older. Subjects with presumed advanced fibrosis (FibroTest greater than 0.48) were re-investigated in a tertiary center. Results The sample characteristics were similar to those of the French population. FibroTest was interpretable in 99.6%. The prevalence of presumed fibrosis was 2.8%, (209/7,463), including cirrhosis in 0.3% (25/7,463); 105/209 (50%) subjects with presumed fibrosis accepted re-investigation. Fibrosis was confirmed in 50, still suspected in 27, indeterminate in 25 and not confirmed with false positive FibroTest or false negative elastography in 3 subjects. False negative rate of FibroTest estimated using elastography was 0.4% (3/766). The attributable causes for confirmed fibrosis were both alcoholic and nonalcoholic fatty liver disease (NAFLD) in 66%, NAFLD in 13%, alcohol in 9%, HCV in 6%, and other in 6%. Factors independently associated (all P < 0.003) with confirmed fibrosis were age, male gender, waist circumference, HCV antibody and alcohol consumption estimated using carbohydrate-deficient transferrin, enabling efficient screening-oriented strategies to be compared and proposed. Conclusions Biomarkers have permitted to estimate prevalence of advanced fibrosis around 2.8% in a general population aged 40 years or older, and several risk factors which may be used for the validation of selective or non-selective screening strategies.

Published
2010
Full Text
View/download PDF

74. Prevalence of mixed cryoglobulins in relation to CD4 cell count among patients coinfected with HIV and hepatitis C virus

Author

Aaron, Laurent, Lebray, Pascal, Alyanakian, Marie-Alexandra, Roudiere, Laurent, Therby, Audrey, Chaix, Marie-Laure, Dupont, Bertrand, Pol, Stanislas, and Viard, Jean-Paul

Subjects
Hepatitis C virus -- Risk factors, Hepatitis C virus -- Care and treatment, HIV infection -- Risk factors, HIV infection -- Care and treatment, Cryoglobulinemia -- Risk factors, Cryoglobulinemia -- Research, Health, Health care industry
Published
2005

75. Predictive value of liver damage for severe early complications and survival after heart transplantation: A retrospective analysis

Author

Lebray, Pascal, primary, Varnous, Shaida, additional, Pascale, Alina, additional, Leger, Philippe, additional, Luyt, Charles Edouard, additional, Ratziu, Vlad, additional, Munteanu, Mona, additional, Ould Amar, Salima, additional, Thabut, Dominique, additional, Chastre, Jean, additional, Pavie, Alain, additional, Poynard, Thierry, additional, and Leprince, Pascal, additional

Published
2018
Full Text
View/download PDF

76. Longterm Risk of Solid Organ De Novo Malignancies After Liver Transplantation: A French National Study on 11,226 Patients

Author

Sérée, Olivier, primary, Altieri, Mario, additional, Guillaume, Elodie, additional, De Mil, Rémy, additional, Lobbedez, Thierry, additional, Robinson, Philip, additional, Segol, Philippe, additional, Salamé, Ephrem, additional, Abergel, Armand, additional, Boillot, Olivier, additional, Conti, Filomena, additional, Chazouillères, Olivier, additional, Debette‐Gratien, Maryline, additional, Debray, Dominique, additional, Hery, Géraldine, additional, Dharancy, Sébastien, additional, Durand, François, additional, Duvoux, Christophe, additional, Francoz, Claire, additional, Gugenheim, Jean, additional, Hardwigsen, Jean, additional, Houssel‐Debry, Pauline, additional, Jacquemin, Emmanuel, additional, Kamar, Nassim, additional, Latournerie, Marianne, additional, Lebray, Pascal, additional, Leroy, Vincent, additional, Mazzola, Alessandra, additional, Neau‐Cransac, Martine, additional, Pageaux, Georges‐Philippe, additional, Radenne, Sylvie, additional, Saliba, Faouzi, additional, Samuel, Didier, additional, Vanlemmens, Claire, additional, Woehl‐Jaegle, Marie‐Lorraine, additional, Launoy, Guy, additional, and Dumortier, Jérôme, additional

Published
2018
Full Text
View/download PDF

77. Evolution of platelet functions in cirrhotic patients undergoing liver transplantation: A prospective exploration over a month

Author

Eyraud, Daniel, primary, Suner, Ludovic, additional, Dupont, Axelle, additional, Bachelot-Loza, Christilla, additional, Smadja, David M., additional, Helley, Dominique, additional, Bertil, Sébastien, additional, Gostian, Ovidiu, additional, Szymezak, Jean, additional, Loncar, Yann, additional, Puybasset, Louis, additional, Lebray, Pascal, additional, Vezinet, Corinne, additional, Vaillant, Jean-Christophe, additional, Granger, Benjamin, additional, and Gaussem, Pascale, additional

Published
2018
Full Text
View/download PDF

78. 12 Weeks of a Ribavirin-Free Sofosbuvir and Nonstructural Protein 5A Inhibitor Regimen Is Enough to Treat Recurrence of Hepatitis C After Liver Transplantation

Author

Houssel-Debry, Pauline, Coilly, Audrey, Fougerou-Leurent, Claire, Jezequel, Caroline, Duvoux, Christophe, De Ledinghen, Victor, Radenne, Sylvie, Kamar, Nassim, Leroy, Vincent, Martino, Vincent Di, D'Alteroche, Louis, Canva, Valérie, Conti, Filomena, Dumortier, Jérôme, Montialoux, Hélène, Lebray, Pascal, Botta-Fridlund, Danielle, Tran, Albert, Moreno, Christophe, Silvain, Christine, Besch, Camille, Perre, Philippe, Francoz, Claire, Abergel, Armando, Habersetzer, François, Debette-Gratien, Maryline, Cagnot, Carole, Diallo, Alpha, Chevaliez, Stéphane, Rossignol, Emilie, Veislinger, Aurélie, Duclos-Vallée, Jean-Charles, Pageaux, Georges-Philippe, Houssel-Debry, Pauline, Coilly, Audrey, Fougerou-Leurent, Claire, Jezequel, Caroline, Duvoux, Christophe, De Ledinghen, Victor, Radenne, Sylvie, Kamar, Nassim, Leroy, Vincent, Martino, Vincent Di, D'Alteroche, Louis, Canva, Valérie, Conti, Filomena, Dumortier, Jérôme, Montialoux, Hélène, Lebray, Pascal, Botta-Fridlund, Danielle, Tran, Albert, Moreno, Christophe, Silvain, Christine, Besch, Camille, Perre, Philippe, Francoz, Claire, Abergel, Armando, Habersetzer, François, Debette-Gratien, Maryline, Cagnot, Carole, Diallo, Alpha, Chevaliez, Stéphane, Rossignol, Emilie, Veislinger, Aurélie, Duclos-Vallée, Jean-Charles, and Pageaux, Georges-Philippe

Abstract

Sofosbuvir (SOF) combined with nonstructural protein 5A (NS5A) inhibitors has demonstrated its efficacy in treating a recurrence of hepatitis C virus (HCV) after liver transplantation (LT). However, the duration of treatment and need for ribavirin (RBV) remain unclear in this population. Our aim was to determine whether LT recipients could be treated with an SOF + NS5A inhibitor-based regimen without RBV for 12 weeks post-LT. Between October 2013 and December 2015, 699 LT recipients experiencing an HCV recurrence were enrolled in the multicenter ANRS CO23 CUPILT cohort. We selected patients receiving SOF and NS5A inhibitor ± RBV and followed for at least 12 weeks after treatment discontinuation. The primary efficacy endpoint was a sustained virological response 12 weeks after the end of treatment (SVR12). Among these 699 patients, 512 fulfilled the inclusion criteria. Their main characteristics were: 70.1% genotype 1, 18.2% genotype 3, 21.1% cirrhosis, and 34.4% previously treated patients. We identified four groups of patients according to their treatment and duration: SOF + NS5A without RBV for 12 (156 patients) or 24 (239 patients) weeks; SOF + NS5A + RBV for 12 (47 patients) or 24 (70 patients) weeks. SVR12 values reached 94.9%, 97.9%, 95.7%, and 92.9%, respectively (P = 0.14). Only 20 patients experienced a treatment failure. Under multivariate analysis, factors such as fibrosis stage, previous treatment, HCV genotype, and baseline HCV viral load did not influence SVR12 rates in the four groups (P = 0.21). Hematological adverse events (AEs) were more common in the RBV group: anemia (P < 0.0001) and blood transfusion (P = 0.0001). Conclusion: SOF + NS5A inhibitors without RBV for 12 weeks constituted reliable therapy for recurrent HCV post-LT with an excellent SVR12 whatever the fibrosis stage, HCV genotype, and previous HCV treatment. (Hepatology 2018; 00:000-000)., SCOPUS: ar.j, info:eu-repo/semantics/published

Published
2018

79. Achieving SVR Does Not Prevent From Fibrosis Progression In Patients With FCH: Results From A Large French Prospective Multicentric ANRS CO23 Cupilt Cohort

Author

Sebagh, Mylene, Fougerou-Leurent, Claire, Pageaux, Georges-Philippe, Leroy, Vincent, Dumortier, Jerome, Radenne, Sylvie, Sylvain, Christine, Lebray, Pascal, Houssel-Debry, Pauline, Cagnot, Carole, Rossignol, Emilie, Danjou, Helene, Veislinger, Aurelie, Samuel, Didier, Duclos-Vallée, Jean-Charles, Coilly, Audrey, AP-HP Hôpital Bicêtre (Le Kremlin-Bicêtre), Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Lapeyronie [Montpellier] (CHU), CHU Grenoble, CHU de Lyon, Université Claude Bernard Lyon 1 (UCBL), Université de Lyon, Hôpital de la Croix-Rousse [CHU - HCL], Hospices Civils de Lyon (HCL), Centre hospitalier universitaire de Poitiers (CHU Poitiers), CHU Paris, CHU Pontchaillou [Rennes], Hôpital Paul Brousse, Physiopathologie et traitement des maladies du foie, Université Paris-Sud - Paris 11 (UP11)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), DHU Hepatinov, Novartis, Astellas, Roche, MSD, GSK, Gilead, Université de Rennes 1 (UR1), and Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM)

Subjects
[SDV]Life Sciences [q-bio], ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2017

80. Sofosbuvir and NS5A inhibitors without Ribavirin during 12 weeks are efficient to treat hepatitis C recurrence after liver transplantation only in genotype 1. Results from the CO23 ANRS CUPILT study

Author

Houssel-Debry, Pauline, Coilly, Audrey, Fougerou-Leurent, Claire, Jezequel, Caroline, Duvoux, Christophe, Ledinghen, Victor, Radenne, Sylvie, Kamar, Nassim, Leroy, Vincent, Di Martino, Vincent, d'Alteroche, Louis, Canva-Delcambre, Valerie, Conti, Filomena, Dumortier, Jérôme, Montialoux, Helene, Lebray, Pascal, Botta-Fridlund, Danielle, Anty, Rodolphe, Moreno, Christophe, Silvain, Christine, Besch, Camille, Perré, Philippe, Francoz, Claire, Abergel, Armand, Habersetzer, François, Debette-Gratien, Maryline, Rohel, Alexandra, Diallo, Alpha, Rossignol, Emilie, Danjou, Helene, Veislinger, Aurelie, Duclos-Vallée, Jean-Charles, Pageaux, Georges-Philippe, Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Paul Brousse, Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse, Centre hépato-biliaire (CHB), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), Physiopathologie et traitement des maladies du foie, Université Paris-Sud - Paris 11 (UP11)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Pontchaillou [Rennes], Service des Maladies de l'Appareil Digestif [CHU Rennes], Pôle Recherche Clinique-Santé Publique [Mondor], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor, Physiopathologie du cancer du foie, Université Bordeaux Segalen - Bordeaux 2-Institut National de la Santé et de la Recherche Médicale (INSERM), Service d'hépatologie, Hospices Civils de Lyon (HCL)-Hôpital de la Croix-Rousse [CHU - HCL], Hospices Civils de Lyon (HCL), Institut de médecine moléculaire de Rangueil (I2MR), Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT)-Université de Toulouse (UT)- Institut Fédératif de Recherche Bio-médicale Institution (IFR150)-Institut National de la Santé et de la Recherche Médicale (INSERM), Département de Néphrologie et Transplantation d'organes [CHU Toulouse], Pôle Urologie - Néphrologie - Dialyse - Transplantations - Brûlés - Chirurgie plastique - Explorations fonctionnelles et physiologiques [CHU Toulouse], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse)-Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), Université Grenoble Alpes - UFR Médecine (UGA UFRM), Université Grenoble Alpes [2016-2019] (UGA [2016-2019]), Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon)-Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC), CHU Trousseau [APHP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), CHU Trousseau [Tours], Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), CHU Pitié-Salpêtrière [AP-HP], Centre de Recherche Saint-Antoine (UMRS893), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Saint-Antoine [AP-HP], service d'Hépato-gastro-entérologie, Hospices Civiles de Lyon-Hôpital Edouard Heriault, Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Université Pierre et Marie Curie - Paris 6 (UPMC), Chirurgie Digestive, Assistance Publique - Hôpitaux de Marseille (APHM)-Hôpital de la Conception [CHU - APHM] (LA CONCEPTION), Centre méditerranéen de médecine moléculaire (C3M), Université Nice Sophia Antipolis (1965 - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Côte d'Azur (UCA), Département Digestif, Centre Hospitalier Universitaire de Nice (CHU Nice)-Hôpital de l'Archet, Hôpital Erasme [Bruxelles] (ULB), Faculté de Médecine [Bruxelles] (ULB), Université libre de Bruxelles (ULB)-Université libre de Bruxelles (ULB), Hôpital de la Milétrie, Centre hospitalier universitaire de Poitiers (CHU Poitiers), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7)-Hôpital Beaujon [AP-HP], Service d'Hépato-Gastro-Entérologie, CHU Estaing [Clermont-Ferrand], CHU Clermont-Ferrand-CHU Clermont-Ferrand, Interactions Virus-Hôte et Maladies Hépatiques, Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut de Virologie, Anti-infectieux : supports moléculaires des résistances et innovations thérapeutiques (RESINFIT), CHU Limoges-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST), Université de Limoges (UNILIM)-Université de Limoges (UNILIM), Hepatinov (DHU), Université Paris-Sud - Paris 11 (UP11)-Centre Hépato-Biliaire Paul Brousse, Centre National de Référence pour la maladie de Wilson (CNR wilson), CNR Wilson, Service de Neurologie, Hôpital Lariboisière, Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Hôpital Saint Eloi (CHRU Montpellier), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), Service des Maladies de l'Appareil Digestif, Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-CHU Pontchaillou [Rennes], Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-IFR150-Institut National de la Santé et de la Recherche Médicale (INSERM), Department of Multiorgan Transplantation, CHU Toulouse [Toulouse], Service de gastro-entérologie [CHU Trousseau], Université Pierre et Marie Curie - Paris 6 (UPMC)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-CHU Trousseau [APHP], Service de Chirurgie Digestive, Hépato-Bilio-pancréatique et Transplantation Hépatique [CHU Pitié-Salpétrière], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-CHU Saint-Eloi, Hôpital Paul Brousse-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris-Sud - Paris 11 (UP11), Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital Paul Brousse-Université Paris-Sud - Paris 11 (UP11), Institut National de la Santé et de la Recherche Médicale (INSERM)-Université Bordeaux Segalen - Bordeaux 2, Université de Franche-Comté (UFC), Université Bourgogne Franche-Comté [COMUE] (UBFC)-Université Bourgogne Franche-Comté [COMUE] (UBFC)-Centre Hospitalier Régional Universitaire de Besançon (CHRU Besançon), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Université Nice Sophia Antipolis (... - 2019) (UNS), COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-COMUE Université Côte d'Azur (2015-2019) (COMUE UCA)-Université Côte d'Azur (UCA)-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Beaujon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST), Université de Limoges (UNILIM)-Université de Limoges (UNILIM)-CHU Limoges, Centre d'Investigation Clinique [Rennes] ( CIC ), Université de Rennes 1 ( UR1 ), Université de Rennes ( UNIV-RENNES ) -Université de Rennes ( UNIV-RENNES ) -Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Université Paris-Sud - Paris 11 ( UP11 ) -Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Paul Brousse, Centre hépato-biliaire ( CHB ), Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Université Paris-Sud - Paris 11 ( UP11 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -AP-HP Hôpital Paul Brousse, Université de Rennes ( UNIV-RENNES ) -Université de Rennes ( UNIV-RENNES ) -Hôpital Pontchaillou-CHU Pontchaillou [Rennes], Assistance publique - Hôpitaux de Paris (AP-HP)-Hôpital Henri-Mondor, Université Bordeaux Segalen - Bordeaux 2-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Hospices Civils de Lyon ( HCL ) -Hôpital de la Croix-Rousse [CHU - HCL], Hospices Civils de Lyon ( HCL ), Institut de médecine moléculaire de Rangueil ( I2MR ), Université Toulouse III - Paul Sabatier ( UPS ), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-IFR150-Institut National de la Santé et de la Recherche Médicale ( INSERM ), Université Grenoble Alpes - UFR Médecine ( UGA UFRM ), Université Grenoble Alpes ( UGA ), Centre Hospitalier Régional Universitaire [Besançon] ( CHRU Besançon ) -Hôpital Jean Minjoz-Université de Franche-Comté ( UFC ), Service de gastro-entérologie, Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Trousseau [APHP], CHRU Tours, Service de chirurgie digestive hépato-bilio-pancréatique transplantation hépatique [CHU Pitié-Salpêtrière], Assistance publique - Hôpitaux de Paris (AP-HP)-CHU Pitié-Salpêtrière [APHP], Centre de Recherche Saint-Antoine ( CR Saint-Antoine ), Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Université Pierre et Marie Curie - Paris 6 ( UPMC ), Human HepCell [AP-HP Hôpital Saint-Antoine], Université Pierre et Marie Curie - Paris 6 ( UPMC ) -Université Paris Descartes - Paris 5 ( UPD5 ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ) -AP-HP - Hôpital Saint-Antoine -Paris Biotech santé, APHP, Université Pierre et Marie Curie - Paris 6 ( UPMC ), Assistance Publique - Hôpitaux de Marseille ( APHM ) -Hôpital de la Conception [CHU - APHM] ( LA CONCEPTION ), Centre méditérannéen de médecine moléculaire ( C3M ), Université Nice Sophia Antipolis ( UNS ), Université Côte d'Azur ( UCA ) -Université Côte d'Azur ( UCA ) -Institut National de la Santé et de la Recherche Médicale ( INSERM ), CHU Nice-Hôpital de l'Archet, Hôpital Erasme, Université Libre de Bruxelles [Bruxelles] ( ULB ), Centre hospitalier universitaire de Poitiers ( CHU Poitiers ), Assistance publique - Hôpitaux de Paris (AP-HP)-Université Paris Diderot - Paris 7 ( UPD7 ) -Hôpital Beaujon, Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Institut de Virologie, Anti-infectieux : supports moléculaires des résistances et innovations thérapeutiques ( RESINFIT ), CHU Limoges-Institut National de la Santé et de la Recherche Médicale ( INSERM ) -Institut Génomique, Environnement, Immunité, Santé, Thérapeutique ( GEIST ), Université de Limoges ( UNILIM ) -Université de Limoges ( UNILIM ), Hepatinov ( DHU ), Université Paris-Sud - Paris 11 ( UP11 ) -Centre Hépato-Biliaire Paul Brousse, Centre National de Référence pour la maladie de Wilson ( CNR wilson ), and Centre Hospitalier Régional Universitaire [Montpellier] ( CHRU Montpellier ) -CHU Saint-Eloi

Subjects
[ SDV ] Life Sciences [q-bio], [SDV]Life Sciences [q-bio], ComputingMilieux_MISCELLANEOUS
Abstract

International audience; Meeting Abstract: 925

Published
2017

81. No evidence of hepatitis B virus reactivation among liver transplant recipients treated with interferon- free regimens for hepatitis C virus recurrence (ANRS CO23 CUPILT Cohort)

Author

Mouna, Lina, Rossignol, Emilie, Tateo, Mariagrazia, Duclos-Vallee, Jean-Charles, Duvoux, Christophe, Durand, Francois, Tran, Albert, Radenne, Sylvie, Canva-Delcambre, Valerie, Houssel-Debry, Pauline, Dumortier, Jérôme, Conti, Filomena, De Ledinghen, Victor, Leroy, Vincent, Kamar, Nassim, Di Martino, Vincent, Moreno, Christophe, Fridlund, Danielle M. Botta, D'Alteroche, Louis, Lebray, Pascal, perre, philippe, Besch, Camille, Silvain, Christine, Habersetzer, François, Debette-Gratien, Maryline, Abergel, Armando, Diallo, Alpha, Roque-Afonso, Anne Marie, Pageaux, Georges-Philippe, Jonchère, Laurent, Hôpital Paul Brousse, Université Paris-Sud - Paris 11 (UP11), Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), Physiopathologie et traitement des maladies du foie, Université Paris-Sud - Paris 11 (UP11)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), DHU Hepatinov, Service d'Hépatologie, Hôpital Henri Mondor, AP-HP, Créteil, France., Hôpital Henri Mondor, Centre Hospitalier Universitaire de Nice (CHU Nice), Service d'hépatogastroentérologie [Hôpital de la Croix-Rousse, Hospices Civils de Lyon], Hôpital de la Croix-Rousse [CHU - HCL], Hospices Civils de Lyon (HCL)-Hospices Civils de Lyon (HCL), CHU Pontchaillou [Rennes], Service d'hépatogastroentérologie [Hôpital Edouard Herriot, Hospices Civils de Lyon], Hôpital Edouard Herriot [CHU - HCL], Hôpital St Antoine, Hôpital Haut-Lévêque, Université Sciences et Technologies - Bordeaux 1-CHU Bordeaux [Bordeaux], Hôpital Michallon, CHU Toulouse [Toulouse], Hôpital Erasme [Bruxelles] (ULB), Faculté de Médecine [Bruxelles] (ULB), Université libre de Bruxelles (ULB)-Université libre de Bruxelles (ULB), CHU Marseille, CHU Trousseau [Tours], Centre Hospitalier Régional Universitaire de Tours (CHRU Tours), CHD Vendee (La Roche Sur Yon), Service d’Hépatogastroentérologie, NHC, CHU de Strasbourg, Centre hospitalier universitaire de Poitiers (CHU Poitiers), Service d'Hépato-Gastro-Entérologie et Nutrition [CHU Limoges], CHU Limoges, CHU Clermont-Ferrand, ANRS France Recherche Nord & sud Sida-hiv hépatites, Hôpital Lapeyronie [Montpellier] (CHU), Novartis, Astellas, Roche, MSD, GSK, Gilead, Supersonic Imagine, Janssen, Abbvie, Schering-Plough, Centre Hospitalier Départemental - Hôpital de La Roche-sur-Yon (CHD Vendée), Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), CHU Saint-Antoine [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Université Sciences et Technologies - Bordeaux 1 (UB)-CHU Bordeaux [Bordeaux], Centre Hospitalier Universitaire de Toulouse (CHU Toulouse), and Institut National de la Santé et de la Recherche Médicale (INSERM)-Hôpital Paul Brousse-Université Paris-Sud - Paris 11 (UP11)

Subjects
[SDV] Life Sciences [q-bio], [SDV]Life Sciences [q-bio], ComputingMilieux_MISCELLANEOUS
Abstract

International audience

Published
2017

83. Diagnostic performance of FibroTest, SteatoTest and ActiTest in patients with NAFLD using the SAF score as histological reference

Author

Munteanu, M., Tiniakos, D., Anstee, Q., Charlotte, F., Marchesini, G., Bugianesi, E., Trauner, M., Romero Gomez, M., Oliveira, C., Day, C., Dufour, J.‐F., Bellentani, S., Ngo, Y., Traussnig, S., Perazzo, H., Deckmyn, O., Bedossa, P., Ratziu, V., Poynard, T., Ratziu, Vlad, Poynard, Thierry, Castille, Jean‐Marie, Ngo, Yen, Langon, Tania, Day, Chris, Tiniakos, Dina, Lawlor, Debbie, Marchesini, Giulio, Marra, Fabio, Bugianesi, Elisabetta, Bellentani, Stefano, Dufour, Jean‐François, Romero Gomez, Manuel, Sørensen, Thorkild, Tribelli, Claudio, De Minicis, Samuele, Trauner, Michael, Oliveira, Claudia, Bedossa, Pierre, Burt, Alastair D., Gouw, Annette S.H., Lackner, Carolin, Schirmacher, Peter, Terracciano, Luigi, Brain, J., Bury, Yvonne, Cabibi, Daniela, Charlotte, Frederic, David, Ezio, Losi, Luisa, Montani, Matteo, Pareja, Marıa Jesus, Wendum, Dominique, Wrba, Fritz, Ziol, Marianne, Thabut, Dominique, Moussalli, Joseph, Lebray, Pascal, Rudler, Marika, Bismuth, Françoise Imbert, Rosmorduc, Olivier, Calmus, Yvon, Hartemann, Agnes, Jacqueminet, Sophie, Bruckert, Eric, Giral, Philippe, Naveau, Sylvie, Perlemuter, Gabriel, Varsat, Brigitte, Mercadier, Anne, Biopredictive, National and Kapodistrian University of Athens (NKUA), Newcastle University [Newcastle], Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Institute of cardiometabolism and nutrition (ICAN), Université Pierre et Marie Curie - Paris 6 (UPMC)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [AP-HP], Sorbonne Université (SU)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Alma Mater Studiorum Università di Bologna [Bologna] (UNIBO), Università degli studi di Torino (UNITO), Medizinische Universität Wien = Medical University of Vienna, Universidad de Sevilla, University of São Paulo School of Medicine, Universität Bern [Bern], Università degli Studi di Modena e Reggio Emilia (UNIMORE), Université Pierre et Marie Curie - Paris 6 (UPMC), Hôpital Beaujon, Hôpital Beaujon [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7), National and Kapodistrian University of Athens = University of Athens (NKUA | UoA), Université Pierre et Marie Curie - Paris 6 (UPMC)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP)-Institut National de la Santé et de la Recherche Médicale (INSERM)-CHU Pitié-Salpêtrière [APHP], Università di Bologna [Bologna] (UNIBO), Hôpital Beaujon-Université Paris Diderot - Paris 7 (UPD7)-Assistance publique - Hôpitaux de Paris (AP-HP) (APHP), Munteanu, M., Tiniakos, D., Anstee, Q., Charlotte, F., MARCHESINI REGGIANI, Giulio, Bugianesi, E., Trauner, M., Romero Gomez, M., Oliveira, C., Day, C., Dufour, J. F., Bellentani, S., Ngo, Y., Traussnig, S., Perazzo, H., Deckmyn, O., Bedossa, P., Ratziu, V., Poynard, T., Unité de Recherche sur les Maladies Cardiovasculaires, du Métabolisme et de la Nutrition = Research Unit on Cardiovascular and Metabolic Diseases (ICAN), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU)-Sorbonne Université (SU), Università degli studi di Torino = University of Turin (UNITO), Universidad de Sevilla / University of Sevilla, Universität Bern [Bern] (UNIBE), Università degli Studi di Modena e Reggio Emilia = University of Modena and Reggio Emilia (UNIMORE), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Université Paris Diderot - Paris 7 (UPD7)-Hôpital Beaujon [AP-HP], and Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)

Subjects
Liver Cirrhosis, Male, medicine.medical_specialty, Biopsy, 610 Medicine & health, Gastroenterology, 03 medical and health sciences, 0302 clinical medicine, Fibrosis, Non-alcoholic Fatty Liver Disease, Internal medicine, medicine, Humans, Pharmacology (medical), Prospective Studies, Stage (cooking), Prospective cohort study, Grading (tumors), Inflammation, Hematologic Tests, Hepatology, medicine.diagnostic_test, business.industry, FibroTest, Fatty liver, Middle Aged, medicine.disease, 3. Good health, Non‐invasive Tests of Nafld, Fatty Liver, 030220 oncology & carcinogenesis, 030211 gastroenterology & hepatology, Original Article, Female, Steatosis, business, [SDV.MHEP]Life Sciences [q-bio]/Human health and pathology
Abstract

the FLIP Consortium and the FibroFrance Group; International audience; BackgroundBlood tests of liver injury are less well validated in non-alcoholic fatty liver disease (NAFLD) than in patients with chronic viral hepatitis.AimsTo improve the validation of three blood tests used in NAFLD patients, FibroTest for fibrosis staging, SteatoTest for steatosis grading and ActiTest for inflammation activity grading.MethodsWe pre-included new NAFLD patients with biopsy and blood tests from a single-centre cohort (FibroFrance) and from the multicentre FLIP consortium. Contemporaneous biopsies were blindly assessed using the new steatosis, activity and fibrosis (SAF) score, which provides a reliable and reproducible diagnosis and grading/staging of the three elementary features of NAFLD (steatosis, inflammatory activity) and fibrosis with reduced interobserver variability. We used nonbinary-ROC (NonBinAUROC) as the main endpoint to prevent spectrum effect and multiple testing.ResultsA total of 600 patients with reliable tests and biopsies were included. The mean NonBinAUROCs (95% CI) of tests were all significant (P < 0.0001): 0.878 (0.864–0.892) for FibroTest and fibrosis stages, 0.846 (0.830–0.862) for ActiTest and activity grades, and 0.822 (0.804–0.840) for SteatoTest and steatosis grades. FibroTest had a higher NonBinAUROC than BARD (0.836; 0.820–0.852; P = 0.0001), FIB4 (0.845; 0.829–0.861; P = 0.007) but not significantly different than the NAFLD score (0.866; 0.850–0.882; P = 0.26). FibroTest had a significant difference in median values between adjacent stage F2 and stage F1 contrarily to BARD, FIB4 and NAFLD scores (Bonferroni test P < 0.05).ConclusionsIn patients with NAFLD, SteatoTest, ActiTest and FibroTest are non-invasive tests that offer an alternative to biopsy, and they correlate with the simple grading/staging of the SAF scoring system across the three elementary features of NAFLD: steatosis, inflammatory activity and fibrosis.

Published
2016
Full Text
View/download PDF

84. Multicenter Experience with Boceprevir or Telaprevir to Treat Hepatitis C Recurrence after Liver Transplantation: When Present Becomes Past, What Lessons for Future?

Author

Coilly, Audrey, Dumortier, Jérôme, Botta-Fridlund, Danielle, Latournerie, Marianne, Leroy, Vincent, Pageaux, Georges-Philippe, Agostini, Hélène, Giostra, Emiliano, Moreno, Christophe, Roche, Bruno, Antonini, Teresa Maria, Guillaud, Olivier, Lebray, Pascal, Radenne, Sylvie, Saouli, Anne-Catherine, Calmus, Yvon, Alric, Laurent, Debette-Gratien, Maryline, De Ledinghen, Victor, Durand, François, Duvoux, Christophe, Samuel, Didier, Duclos-Vallee, Jean-Charles, Hôpital Paul Brousse, Université Paris-Sud - Paris 11 (UP11)-Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse, Centre hépato-biliaire (CHB), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), service d'Hépato-gastro-entérologie, Hospices Civiles de Lyon-Hôpital Edouard Heriault, Chirurgie Digestive, Assistance Publique - Hôpitaux de Marseille (APHM)-Hôpital de la Conception [CHU - APHM] (LA CONCEPTION), Centre d'Investigation Clinique [Rennes] (CIC), Université de Rennes 1 (UR1), Université de Rennes (UNIV-RENNES)-Université de Rennes (UNIV-RENNES)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), Hôpital Michallon, Cellules Souches, Plasticité Cellulaire, Médecine Régénératrice et Immunothérapies (IRMB), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Université de Montpellier (UM), Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Hôpital Erasme [Bruxelles] (ULB), Faculté de Médecine [Bruxelles] (ULB), Université libre de Bruxelles (ULB)-Université libre de Bruxelles (ULB), CHU Pitié-Salpêtrière [AP-HP], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP), Service d'hépatologie, Hospices Civils de Lyon (HCL)-Hôpital de la Croix-Rousse [CHU - HCL], Hospices Civils de Lyon (HCL), Centre de Recherche Saint-Antoine (UMRS893), Université Pierre et Marie Curie - Paris 6 (UPMC)-Institut National de la Santé et de la Recherche Médicale (INSERM), Pharmacochimie et Biologie pour le Développement (PHARMA-DEV), Institut de Recherche pour le Développement (IRD)-Institut de Chimie de Toulouse (ICT-FR 2599), Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées, Anti-infectieux : supports moléculaires des résistances et innovations thérapeutiques (RESINFIT), CHU Limoges-Institut National de la Santé et de la Recherche Médicale (INSERM)-Institut Génomique, Environnement, Immunité, Santé, Thérapeutique (GEIST), Université de Limoges (UNILIM)-Université de Limoges (UNILIM), Hôpital Beaujon [AP-HP], Pôle Recherche Clinique-Santé Publique [Mondor], Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Hôpital Henri Mondor, Physiopathologie et traitement des maladies du foie, Université Paris-Sud - Paris 11 (UP11)-Hôpital Paul Brousse-Institut National de la Santé et de la Recherche Médicale (INSERM), Hepatinov (DHU), Université Paris-Sud - Paris 11 (UP11)-Centre Hépato-Biliaire Paul Brousse, Université de Rennes (UR)-Hôpital Pontchaillou-Institut National de la Santé et de la Recherche Médicale (INSERM), Assistance publique - Hôpitaux de Paris (AP-HP) (AP-HP)-Sorbonne Université (SU), Institut de Recherche pour le Développement (IRD)-Institut de Chimie de Toulouse (ICT), Université de Toulouse (UT)-Université de Toulouse (UT)-Institut de Chimie du CNRS (INC)-Centre National de la Recherche Scientifique (CNRS)-Institut National Polytechnique (Toulouse) (Toulouse INP), Université de Toulouse (UT)-Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université de Toulouse (UT), Université de Montpellier (UM)-Institut National de la Santé et de la Recherche Médicale (INSERM)-Centre Hospitalier Régional Universitaire [Montpellier] (CHRU Montpellier), Institut National Polytechnique (Toulouse) (Toulouse INP), Université Fédérale Toulouse Midi-Pyrénées-Université Fédérale Toulouse Midi-Pyrénées-Centre National de la Recherche Scientifique (CNRS)-Institut de Recherche pour le Développement (IRD)-Université Toulouse III - Paul Sabatier (UT3), Université Fédérale Toulouse Midi-Pyrénées-Institut de Chimie du CNRS (INC)-Institut National Polytechnique (Toulouse) (Toulouse INP), and Université Fédérale Toulouse Midi-Pyrénées-Institut de Chimie du CNRS (INC)

Subjects
Male, Adult, Genotype, Proline, [SDV]Life Sciences [q-bio], Psychologie appliquée, lcsh:Medicine, Hepacivirus, Antiviral Agents, Polyethylene Glycols, Drug Therapy, Recurrence, Humans, Protease Inhibitors, Postoperative Period, Prospective Studies, lcsh:Science, Aged, lcsh:R, Interferon-alpha, Anemia, Sciences bio-médicales et agricoles, Middle Aged, Combined Modality Therapy, Thrombocytopenia, Recombinant Proteins, Liver Transplantation, Treatment Outcome, Multivariate Analysis, Combination, Host-Pathogen Interactions, HEPATITIS C, Drug Therapy, Combination, lcsh:Q, Female, Biologie, Oligopeptides, Research Article
Abstract

Background and aims First generation protease inhibitors (PI) with peg-interferon (PEG-IFN) and ribavirin (RBV) have been the only therapy available for hepatitis C virus (HCV) genotype 1 infection in most countries for 3 years. We have investigated the efficacy and tolerance of this triple therapy in transplanted patients experiencing a recurrence of HCV infection on the liver graft. Patients This cohort study enrolled 81 liver transplant patients (Male: 76%, mean age: 55.8±9.7 years) with severe HCV recurrence (F3 or F4: n = 34 (42%), treatment experienced: n = 44 (54%)), treated with boceprevir (n = 36; 44%) or telaprevir (n = 45; 56%). We assessed the percentages of patients with sustained virological responses 24 weeks after therapy (SVR24), and safety. Results The SVR24 rate was 47% (telaprevir: 42%; boceprevir: 53%, P = ns). At baseline, a normal bilirubin level (p = 0.0145) and albumin level >35g/L (p = 0.0372) and an initial RBV dosage of >800 mg/day (p = 0.0033) predicted SVR24. During treatment, achieving an early virological response after 12 weeks was the strongest independent factor to predict SVR24 (p>0.0001). A premature discontinuation of anti-HCV therapy due to a serious adverse event (SAE) was observed in 22 patients (27%). Hematological toxicity, infections and deaths were observed in 95%, 28% and 7% of patients, respectively. A history of post-LT antiviral therapy and thrombocytopenia (>50G/L) during treatment were both independent predictors of the occurrence of infections or SAE (p = 0.0169 and p = 0.011). Conclusions The use of first generation PI after liver transplantation enabled an SVR24 rate of 47% in genotype 1 patients, but induced a high rate of SAE. The identification of predictive factors for a response to treatment, and the occurrence of SAE, have enabled us to establish limits for the use of this anti-HCV therapy in the transplant setting., SCOPUS: ar.j, info:eu-repo/semantics/published

Published
2015
Full Text
View/download PDF

85. Efficacy and safety of boceprevir-based triple therapy in HCV cirrhotic patients awaiting liver transplantation (ANRS HC29 BOCEPRETRANSPLANT)

Author

Fontaine, Hélène, primary, Maynard, Marianne, additional, Bouix, Cécile, additional, Carrieri, Maria Patrizia, additional, Botta-Fridlund, Danielle, additional, D’Alteroche, Louis, additional, Conti, Filomena, additional, Pageaux, Georges-Philippe, additional, Leroy, Vincent, additional, Métivier, Sophie, additional, Anty, Rodolphe, additional, Durand, François, additional, Canva, Valérie, additional, Vilotitch, Antoine, additional, Lebray, Pascal, additional, Alric, Laurent, additional, Duvoux, Christophe, additional, Petrov-Sanchez, Ventzislava, additional, Beaulieux, Frédérik, additional, Wellems, Célia, additional, Paul, Christelle, additional, Roque-Afonso, Anne-Marie, additional, Roche, Bruno, additional, Pradat, Pierre, additional, Samuel, Didier, additional, Duclos-Vallée, Jean-Charles, additional, Bailly, François, additional, Dharancy, Sébastien, additional, Grangé, Jean-Didier, additional, Guidoum, Amir, additional, Hezode, Christophe, additional, Serfaty, Lawrence, additional, Si-Ahmed, Si-Nafa, additional, Sizorn, Michelle, additional, Taburet, Anne-Marie, additional, and Teicher, Elina, additional

Published
2017
Full Text
View/download PDF

86. Sofosbuvir-based treatment of hepatitis C with severe fibrosis (METAVIR F3/F4) after liver transplantation

Author

Dumortier, Jérôme, Canva, Valérie, Di Martino, Vincent, Conti, Filomena, Kamar, Nassim, Moreno, Christophe, Lebray, Pascal, Tran, Albert, Besch, Camille, Diallo, Mamadou Alpha, Rohel, Alexandra, Leroy, Vincent, Rossignol, Emilie, Abergel, Armando, Botta-Fridlund, Danielle, Coilly, Audrey, Samuel, Didier, Duclos-Vallée, Jean-Charles, Pageaux, Georges-Philippe, Duvoux, Christophe, De Ledinghen, Victor, Francoz, Claire, Houssel-Debry, Pauline, Radenne, Sylvie, D'Alteroche, Louis, Fougerou-Leurent, Claire, Dumortier, Jérôme, Canva, Valérie, Di Martino, Vincent, Conti, Filomena, Kamar, Nassim, Moreno, Christophe, Lebray, Pascal, Tran, Albert, Besch, Camille, Diallo, Mamadou Alpha, Rohel, Alexandra, Leroy, Vincent, Rossignol, Emilie, Abergel, Armando, Botta-Fridlund, Danielle, Coilly, Audrey, Samuel, Didier, Duclos-Vallée, Jean-Charles, Pageaux, Georges-Philippe, Duvoux, Christophe, De Ledinghen, Victor, Francoz, Claire, Houssel-Debry, Pauline, Radenne, Sylvie, D'Alteroche, Louis, and Fougerou-Leurent, Claire

Abstract

Recurrence of hepatitis C virus (HCV) after liver transplantation (LT) can rapidly lead to liver graft cirrhosis and, therefore, graft failure and retransplantation or death. The aim of the present study was to assess efficacy and tolerance of sofosbuvir (SOF)–based regimens for the treatment of HCV recurrence in patients with severe fibrosis after LT. The Compassionate Use of Protease Inhibitors in Viral C Liver Transplantation (CULPIT) study is a prospective multicenter cohort including patients with HCV recurrence following LT treated with second generation direct antivirals. The present study focused on patients included between October 2013 and November 2014 and diagnosed with HCV recurrence and liver graft extensive fibrosis (METAVIR F3/F4). A SOF-based regimen was administered to 125 patients fulfilling inclusion criteria. The median delay from LT was 95.9 ± 69.6 months. The characteristics of patients were as follows: mean age, 59.4 ± 9.0 years; 78.4% male; infected by HCV genotype 1: 78.2%, mean HCV RNA: 6.1 ± 1.0 log10 IU/mL. Eighty patients had failed previous post-LT antiviral therapy (64.0%) including triple therapy with first generation protease inhibitors in 19 (15.2%) patients. The main combination regimen was SOF/daclatasvir (73.6%). Ribavirin was used in 60 patients. Sustained virological response 12 weeks after treatment was 92.8% (on an intention-to-treat basis); 7 patients with virological failure were observed. Serious adverse events occurred in 25.6% of the patients during antiviral treatment. During antiviral treatment and follow-up, 3 patients were retransplanted and 4 patients died. In conclusion, SOF-based antiviral treatment shows very promising results in patients with HCV recurrence and severe fibrosis after LT. Liver Transplantation 22 1367–1378 2016 AASLD., SCOPUS: ar.j, FLWIN, info:eu-repo/semantics/published

Published
2016

87. Sofosbuvir‐based treatment of hepatitis C with severe fibrosis (METAVIR F3/F4) after liver transplantation

Author

Dumortier, Jérôme, primary, Leroy, Vincent, additional, Duvoux, Christophe, additional, de Ledinghen, Victor, additional, Francoz, Claire, additional, Houssel‐Debry, Pauline, additional, Radenne, Sylvie, additional, d'Alteroche, Louis, additional, Fougerou‐Leurent, Claire, additional, Canva, Valérie, additional, di Martino, Vincent, additional, Conti, Filomena, additional, Kamar, Nassim, additional, Moreno, Christophe, additional, Lebray, Pascal, additional, Tran, Albert, additional, Besch, Camille, additional, Diallo, Alpha, additional, Rohel, Alexandra, additional, Rossignol, Emilie, additional, Abergel, Armand, additional, Botta‐Fridlund, Danielle, additional, Coilly, Audrey, additional, Samuel, Didier, additional, Duclos‐Vallée, Jean‐Charles, additional, and Pageaux, Georges‐Philippe, additional

Published
2016
Full Text
View/download PDF

88. LCR1 and LCR2, two multi‐analyte blood tests to assess liver cancer risk in patients without or with cirrhosis.

Author

Poynard, Thierry, Peta, Valentina, Deckmyn, Olivier, Munteanu, Mona, Moussalli, Joseph, Ngo, Yen, Rudler, Marika, Lebray, Pascal, Pais, Raluca, Bonyhay, Luminita, Charlotte, Frederic, Thibault, Vincent, Fartoux, Laetitia, Lucidarme, Olivier, Eyraud, Daniel, Scatton, Olivier, Savier, Eric, Valantin, Marc Antoine, Ngo, An, and Drane, Fabienne

Subjects
BLOOD testing, LIVER cancer patients, DISEASE risk factors, CIRRHOSIS of the liver, ALPHA fetoproteins
Abstract

Summary: Background: No blood test has been shown to be effective in the prediction of primary liver cancer in patients without cirrhosis. Aim: To construct and internally validate two sequential tests for early prediction of liver cancer. These tests enable an algorithm which could improve the performance of the standard surveillance protocol recommended (imaging with or without AFP), limited to patients with cirrhosis. Methods: We performed a retrospective analysis in prospectively collected specimens from an ongoing cohort. We designed an early sensitive high‐risk test (LCR1) that combined (using Cox model) hepatoprotective proteins (apolipoproteinA1, haptoglobin) with known risk factors (gender, age, gammaglutamyltranspeptidase), and a marker of fibrosis (alpha2‐macroglobulin). To increase the specificity, we then combined (LCR2) these components with alpha‐fetoprotein. Results: A total of 9892 patients, 85.9% without cirrhosis, were followed up for 5.9 years [IQR: 4.3‐9.4]. LCR1 and LCR2 time‐dependent AUROCs were not different in construction and validation randomised subsets. Among 2027 patients with high‐LCR1 then high‐LCR2, 167 cancers (113 with cirrhosis, 54 without cirrhosis) were detected, that is 12 patients needed to screen one cancer. The negative predictive value was 99.5% (95% CI 99.0‐99.7) in the 2026 not screened patients (11 cancers without cirrhosis) higher than the standard surveillance, which detected 113 cancers in 755 patients screened, that is seven patients needed to screen one cancer, but with a lower negative predictive value 98.0% (97.5‐98.5; Z = 4.3; P < 0.001) in 3298 not screened patients (42 cancers without cirrhosis). Conclusions: In patients with chronic liver disease the LCR1 and LCR2 tests identify those with a high risk of liver cancer, including in those without cirrhosis. NCT01927133. [ABSTRACT FROM AUTHOR]

Published
2019
Full Text
View/download PDF

89. Long‐term prognostic value of the FibroTest in patients with non‐alcoholic fatty liver disease, compared to chronic hepatitis C, B, and alcoholic liver disease.

Author

Munteanu, Mona, Pais, Raluca, Peta, Valentina, Deckmyn, Olivier, Moussalli, Joseph, Ngo, Yen, Rudler, Marika, Lebray, Pascal, Charlotte, Frederic, Thibault, Vincent, Lucidarme, Olivier, Ngo, An, Imbert‐Bismut, Françoise, Housset, Chantal, Thabut, Dominique, Ratziu, Vlad, and Poynard, Thierry

Subjects
BIOLOGICAL tags, LIVER diseases, PATIENTS, DEATH, CLINICAL trials
Abstract

Summary: Background: Although the FibroTest has been validated as a biomarker to determine the stage of fibrosis in non‐alcoholic fatty liver disease (NAFLD) with results similar to those in chronic hepatitis C (CHC), B (CHB), and alcoholic liver disease (ALD), it has not yet been confirmed for the prediction of liver‐related death. Aim: To validate the 10‐year prognostic value of FibroTest in NAFLD for the prediction of liver‐related death. Method: Patients in the prospective FibroFrance cohort who underwent a FibroTest between 1997 and 2012 were pre‐included. Mortality status was obtained from physicians, hospitals or the national register. Survival analyses were based on univariate (Kaplan‐Meier, log rank, AUROC) and multivariate Cox risk ratio taking into account age, sex and response to anti‐viral treatment as covariates. The comparator was the performance of the FibroTest in CHC, the most validated population. Results: 7082 patients were included; 1079, 3449, 2051, and 503 with NAFLD, CHC, CHB, and ALD, respectively. Median (range) follow‐up was 6.0 years (0.1‐19.3). Ten year survival (95% CI) without liver‐related death in patients with NAFLD was 0.956 (0.940‐0.971; 38 events) and 0.832 (0.818‐0.847; 226 events; P = 0.004) in CHC. The prognostic value (AUROC / Cox risk ratio) of FibroTest in patients with NAFLD was 0.941 (0.905‐0.978)/1638 (342‐7839) and even higher than in patients with CHC 0.875 (0.849‐0.901; P = 0.01)/2657 (993‐6586). Conclusions: The FibroTest has a high prognostic value in NAFLD for the prediction of liver‐related death. (ClinicalTrials.gov number, NCT01927133). [ABSTRACT FROM AUTHOR]

Published
2018
Full Text
View/download PDF

90. 12 Weeks of a Ribavirin‐Free Sofosbuvir and Nonstructural Protein 5A Inhibitor Regimen Is Enough to Treat Recurrence of Hepatitis C After Liver Transplantation.

Author

Houssel‐Debry, Pauline, Coilly, Audrey, Fougerou‐Leurent, Claire, Jezequel, Caroline, Duvoux, Christophe, De Ledinghen, Victor, Radenne, Sylvie, Kamar, Nassim, Leroy, Vincent, Martino, Vincent Di, D'Alteroche, Louis, Canva, Valérie, Conti, Filomena, Dumortier, Jerome, Montialoux, Hélène, Lebray, Pascal, Botta‐Fridlund, Danielle, Tran, Albert, Moreno, Christophe, and Silvain, Christine

Published
2018
Full Text
View/download PDF

91. Rate of employment after liver transplantation in France

Author

Rudler, Marika, primary, Rousseau, Géraldine, additional, Lebray, Pascal, additional, Méténier, Océane, additional, Vaillant, Jean-Christophe, additional, Savier, Eric, additional, Eyraud, Daniel, additional, Poynard, Thierry, additional, and Thabut, Dominique, additional

Published
2016
Full Text
View/download PDF

93. Reply to Perrella et al

Author

Aaron, Laurent, Lebray, Pascal, Alyanakian, Marie-Alexandra, Roudiere, Laurent, Therby, Audrey, Chaix, Marie-Laure, Dupont, Bertrand, Pol, Stanislas, and Viard, Jean-Paul

Subjects
Hepatitis C virus -- Risk factors, Hepatitis C virus -- Research, T cells -- Research, Health, Health care industry
Published
2005

95. Factors associated with chronic hepatitis in patients with hepatitis E virus infection who have received solid organ transplants

Author

UCL - (SLuc) Service de néphrologie, Kamar, Nassim, Garrouste, Cyril, Haagsma, Elizabeth B, Garrigue, Valérie, Pischke, Sven, Chauvet, Cécile, Dumortier, Jérome, Cannesson, Amélie, Cassuto-Viguier, Elisabeth, Thervet, Eric, Conti, Filomena, Lebray, Pascal, Dalton, Harry R, Santella, Robert, Kanaan, Nada, Essig, Marie, Mousson, Christiane, Radenne, Sylvie, Roque-Afonso, Anne Marie, Izopet, Jacques, Rostaing, Lionel, UCL - (SLuc) Service de néphrologie, Kamar, Nassim, Garrouste, Cyril, Haagsma, Elizabeth B, Garrigue, Valérie, Pischke, Sven, Chauvet, Cécile, Dumortier, Jérome, Cannesson, Amélie, Cassuto-Viguier, Elisabeth, Thervet, Eric, Conti, Filomena, Lebray, Pascal, Dalton, Harry R, Santella, Robert, Kanaan, Nada, Essig, Marie, Mousson, Christiane, Radenne, Sylvie, Roque-Afonso, Anne Marie, Izopet, Jacques, and Rostaing, Lionel

Abstract

BACKGROUND & AIMS: Hepatitis E virus (HEV) infection can cause chronic hepatitis in recipients of solid organ transplants. However, the factors that contribute to chronic infection and the outcomes of these patients are incompletely understood. We performed a retrospective analysis of data from 17 centers from Europe and the United States that described the progression, outcomes, and factors associated with development of chronic HEV infection in recipients of transplanted solid organs. METHODS: We studied data from 85 recipients of solid organ transplants who were infected with HEV. Chronic HEV infection was defined by the persistent increases in levels of liver enzymes and polymerase chain reaction evidence of HEV in the serum and/or stool for at least 6 months. RESULTS: Fifty-six patients (65.9%) developed chronic hepatitis. Univariate analysis associated liver transplant, shorter times since transplant, lower levels of liver enzymes and serum creatinine, lower platelet counts, and tacrolimus-based immunosuppressive therapy (rather than cyclosporin A) with chronic hepatitis. On multivariate analysis, the independent predictive factors associated with chronic HEV infection were the use of tacrolimus rather than cyclosporin A (odds ratio [OR], 1.87; 95% confidence interval [CI], 1.49-1.97; P = .004) and a low platelet count at the time of diagnosis with HEV infection (OR, 1.02; 95% CI, 1.001-1.1; P = .04). Of patients with chronic hepatitis, 18 (32.1%) achieved viral clearance after the dose of immunosuppressive therapy was reduced. No HEV reactivation was observed after HEV clearance. CONCLUSIONS: HEV infection causes chronic hepatitis in more than 60% of recipients of solid organ transplants. Tacrolimus therapy is the main predictive factor for chronic hepatitis. Dose reductions of immunosuppressive therapy resulted in viral clearance in more than 30% of patients.

Published
2011

96. FibroTest® and Fibroscan® performances revisited in patients with chronic hepatitis C. Impact of the spectrum effect and the applicability rate

Author

Poynard, Thierry, primary, de Ledinghen, Victor, additional, Zarski, Jean-Pierre, additional, Stanciu, Carol, additional, Munteanu, Mona, additional, Vergniol, Julien, additional, France, Julie, additional, Trifan, Anca, additional, Moussalli, Joseph, additional, Lebray, Pascal, additional, Thabut, Dominique, additional, and Ratziu, Vlad, additional

Published
2011
Full Text
View/download PDF

97. Prevalence of liver fibrosis and risk factors in a general population using non-invasive biomarkers (FibroTest)

Author

Poynard, Thierry, primary, Lebray, Pascal, additional, Ingiliz, Patrick, additional, Varaut, Anne, additional, Varsat, Brigitte, additional, Ngo, Yen, additional, Norha, Pascal, additional, Munteanu, Mona, additional, Drane, Fabienne, additional, Messous, Djamila, additional, Bismut, Françoise Imbert, additional, Carrau, Jean Pierre, additional, Massard, Julien, additional, Ratziu, Vlad, additional, and Giordanella, Jean Pierre, additional

Published
2010
Full Text
View/download PDF

99. Concordance in a World without a Gold Standard: A New Non-Invasive Methodology for Improving Accuracy of Fibrosis Markers

Author

Poynard, Thierry, primary, Ingiliz, Patrick, additional, Elkrief, Laure, additional, Munteanu, Mona, additional, Lebray, Pascal, additional, Morra, Rachel, additional, Messous, Djamila, additional, Bismut, Francoise Imbert, additional, Roulot, Dominique, additional, Benhamou, Yves, additional, Thabut, Dominique, additional, and Ratziu, Vlad, additional

Published
2008
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results